William Blair Weighs in on Align Technology, Inc.’s Q1 2025 Earnings (NASDAQ:ALGN)

Align Technology, Inc. (NASDAQ:ALGN) – Stock analysts at William Blair lifted their Q1 2025 earnings estimates for Align Technology in a research report issued on Wednesday, April 24th. William Blair analyst B. Vazquez now forecasts that the medical equipment provider will post earnings per share of $1.93 for the quarter, up from their previous forecast of $1.78. The consensus estimate for Align Technology’s current full-year earnings is $7.69 per share. William Blair also issued estimates for Align Technology’s Q2 2025 earnings at $2.21 EPS, Q3 2025 earnings at $2.34 EPS and Q4 2025 earnings at $2.53 EPS.

A number of other equities analysts also recently weighed in on the stock. Robert W. Baird raised their target price on shares of Align Technology from $333.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday. Morgan Stanley raised their target price on shares of Align Technology from $344.00 to $360.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group raised their target price on shares of Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a research note on Monday, April 15th. Piper Sandler reaffirmed an “overweight” rating and set a $375.00 target price (up previously from $355.00) on shares of Align Technology in a research note on Thursday. Finally, The Goldman Sachs Group raised their target price on shares of Align Technology from $197.00 to $225.00 and gave the company a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $353.00.

Align Technology Price Performance

Shares of ALGN opened at $309.02 on Monday. Align Technology has a one year low of $176.34 and a one year high of $413.20. The company has a 50-day simple moving average of $313.38 and a two-hundred day simple moving average of $270.82. The firm has a market capitalization of $23.25 billion, a PE ratio of 50.91, a price-to-earnings-growth ratio of 5.53 and a beta of 1.65.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $1.91 EPS for the quarter, topping the consensus estimate of $1.78 by $0.13. Align Technology had a net margin of 11.80% and a return on equity of 14.15%. The business had revenue of $956.73 million during the quarter, compared to analyst estimates of $928.57 million.

Insiders Place Their Bets

In other Align Technology news, Director Joseph Lacob sold 15,000 shares of Align Technology stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total value of $4,548,300.00. Following the completion of the sale, the director now owns 131,994 shares of the company’s stock, valued at approximately $40,023,220.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Emory Wright sold 2,524 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total transaction of $725,523.80. Following the completion of the sale, the executive vice president now owns 709 shares of the company’s stock, valued at approximately $203,802.05. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Joseph Lacob sold 15,000 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total transaction of $4,548,300.00. Following the sale, the director now directly owns 131,994 shares of the company’s stock, valued at approximately $40,023,220.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,524 shares of company stock valued at $8,403,924. Company insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Align Technology

A number of hedge funds have recently modified their holdings of the business. Moody National Bank Trust Division grew its position in shares of Align Technology by 1.8% during the 1st quarter. Moody National Bank Trust Division now owns 2,107 shares of the medical equipment provider’s stock valued at $691,000 after acquiring an additional 38 shares during the period. EFG Asset Management Americas Corp. boosted its holdings in Align Technology by 3.6% in the 4th quarter. EFG Asset Management Americas Corp. now owns 1,167 shares of the medical equipment provider’s stock worth $320,000 after buying an additional 41 shares during the period. Dfpg Investments LLC boosted its holdings in Align Technology by 3.3% in the 4th quarter. Dfpg Investments LLC now owns 1,327 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 42 shares during the period. Richard W. Paul & Associates LLC boosted its holdings in Align Technology by 2.8% in the 4th quarter. Richard W. Paul & Associates LLC now owns 1,669 shares of the medical equipment provider’s stock worth $457,000 after buying an additional 45 shares during the period. Finally, Valley National Advisers Inc. boosted its holdings in Align Technology by 29.7% in the 3rd quarter. Valley National Advisers Inc. now owns 214 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 49 shares during the period. Institutional investors own 88.43% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.